NCT06417099CompletedPhase 2
Efficacy of Dihydroartemisinin for Treating PCOS
Therapeutic Efficacy of Dihydroartemisinin in Patients With Polycystic Ovary Syndrome
Source: ClinicalTrials.gov · Last updated 23 Apr 2025
Brief summary (registry, in English)
The primary research hypothesis of this study is that dihydroartemisinin is effective in restoration of regular menstrual cycles of PCOS subjects who meet at least two of three Rotterdam Criteria. Secondary research hypotheses include: dihydroartemisinin is also effective in reducing androgen, total immature follicles, and anti-Mullerian hormone.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 12 May 2024
- Start date
- 24 May 2024
- Primary completion date
- 30 Mar 2025
- Lead sponsor
- Shanghai Zhongshan Hospital
- NCT number
- NCT06417099
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 30
- From 24 May 2024 to the primary completion date, 30 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other endocrine diseases that can cause secondary PCOS, including but not limited to: 21 hydroxylase deficiency, prolactinoma, hypothyroidism, Cushing's syndrome, etc.
- Patients with other serious diseases affecting heart, liver, kidney, or other major organs.
- Patients with any type of cancer.
Other
- Pregnancy.
Who the study is looking for
- BMI 18.5-28kg/M2
- No plan for pregnancy in the coming 6 months
- Patients should meet two of the three following criteria:
- Irregular cycles and ovulatory dysfunction: \< 21 or \> 35 days or \< 8 cycles per year; \> 90 days for any one cycle
- Polycystic ovaries: ≥12 follicles in at least one of two ovaries (diameter\<10mm), confirmed by ultrasound.
- Elevated androgen levels: total testosterone\>1.67 nmol/L.
Age in the registry: 18 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.